10-K · February 25, 2026
RxSight positions its Light Adjustable Lens (LAL) system as a differentiated premium IOL that enables post‑operative tuning and claims superior clinical outcomes (e.g., 70% of LAL patients achieved 20/20 uncorrected…
Earnings analysis · 10-Q
RXST earnings analysis
Filed May 6, 2026 · Our reading of the company's report
The latest report
RxSight experienced a significant revenue decline of 18.5% YoY, falling to $30.9 million in Q1 2026 from $37.9 million the previous year, largely due to lower unit volumes of LDDs. The gross margin improved to 76.1%…
Read full summary
RxSight experienced a significant revenue decline of 18.5% YoY, falling to $30.9 million in Q1 2026 from $37.9 million the previous year, largely due to lower unit volumes of LDDs. The gross margin improved to 76.1% from 74.8%, but increased operating losses further strained financial metrics, highlighting ongoing challenges despite a cash position of $217.9 million sufficient for at least 12 months of operations.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.38
- Gross margin
- 76.1%
What stood out
-
Significant Revenue Decline
Revenue fell to $30.9 million, down 18.5% YoY from $37.9 million.
-
Improved Gross Margin
Gross margin rose to 76.1%, an increase from 74.8% a year ago.
-
Increased Operating Losses
Operating loss rose to $17.8 million from $10.7 million, up 67% YoY.
-
Cash Position Solid
Cash and equivalents were reported at $217.9 million, deemed sufficient for at least the next 12 months.
-
Investments in Sales Growth
Management emphasizes efforts to increase LDD sold and enhance sales representatives for growth.
-
R&D Expenses Decline
R&D expenses decreased 8.6% YoY to $9.5 million for Q1 2026.
What to watch
-
Ongoing Operating Losses
Continuous losses amounted to $17.8 million in Q1 2026, deepening the accumulated deficit to $676.9 million.
-
Regulatory Challenges
Changes in regulations, including the transition to the EU MDR, could complicate future product approvals.
-
Dependence on Third-Party Suppliers
Reliance on single source suppliers increases vulnerability to supply disruptions.
Management's outlook
Management expects to grow revenues but offers no specific numerical guidance.
Earlier filings 4
10-Q · May 7, 2025
RxSight reported Q1 sales of $37,895,000 (vs. $29,512,000 a year ago), with gross profit of $28,329,000 (gross margin 74.8%) and a net loss per share of $(0.20) compared with $(0.25) in Q1 2024. Operating loss was…
10-Q · May 6, 2024
RxSight reported strong top-line growth and materially improved margins in Q1: revenue rose to $29,512,000 (from $17,489,000 a year ago) and gross margin expanded to 70.1%. Operating and net losses narrowed (loss from…
10-K · February 28, 2024
RxSight positions itself as the developer of the first and only commercially available adjustable premium intraocular lens system (RxSight LAL + LDD) that enables post‑surgical customization of vision. The 10‑K…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.